内容紹介
Summary
Chemotherapy with TAS-102 with bevacizumab(Bmab)is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography(CT)after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.
要旨
症例は67歳,男性。嘔気,嘔吐にて当院を受診し,精査にて直腸癌による腸閉塞,多発肝転移と診断した。人工肛門造設術後に五次治療としてbevacizumab(Bmab)+TAS-102療法を行った。3か月後のCT検査では13%の腫瘍縮小効果を認めた。Bmab+TAS-102療法中のGrade 3以上の有害事象は好中球減少のみであった。6か月後のCT検査では肝転移の増大を認めたが,癌化学療法開始から40か月生存中である。Bmab+TAS-102療法は標準治療抵抗性となった切除不能進行大腸癌に対する治療法として有効な選択肢となり得る。
目次
Chemotherapy with TAS-102 with bevacizumab(Bmab)is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography(CT)after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.
要旨
症例は67歳,男性。嘔気,嘔吐にて当院を受診し,精査にて直腸癌による腸閉塞,多発肝転移と診断した。人工肛門造設術後に五次治療としてbevacizumab(Bmab)+TAS-102療法を行った。3か月後のCT検査では13%の腫瘍縮小効果を認めた。Bmab+TAS-102療法中のGrade 3以上の有害事象は好中球減少のみであった。6か月後のCT検査では肝転移の増大を認めたが,癌化学療法開始から40か月生存中である。Bmab+TAS-102療法は標準治療抵抗性となった切除不能進行大腸癌に対する治療法として有効な選択肢となり得る。